38th week of 2011 patent applcation highlights part 39 |
Patent application number | Title | Published |
20110229499 | METHOD FOR TREATMENT OF VASCULAR HYPERPERMEABILITY - A method for treating or preventing hemorrhagic shock comprising administering a composition comprising stem cells or a soluble factor produced by stem cells, such as stem cell factor (SCF) to a subject. For example, stem cells for use according to the invention can express elevated levels of an anti-apoptotic protein. | 2011-09-22 |
20110229500 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES - The present invention relates to compounds of formula (I): | 2011-09-22 |
20110229501 | ORGANIC COMPOUNDS - The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C | 2011-09-22 |
20110229502 | Ablative immunotherapy - The invention disclosed herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues by first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing necrosis or apoptosis in a tumor or pathogen infected lesion by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue, and then delivering one or more doses of allogeneic cells (e.g., Th1 cells) within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen. | 2011-09-22 |
20110229503 | Vaccination against malignant melanoma using bcg and/or vaccinia - The present invention relates to a vaccination which reduces the risk to contract melanoma to about half to third and moreover, within a five year period post diagnosis of malignant melanoma the risk to die is reduced to about half as compared to the non-vaccinated individuals. | 2011-09-22 |
20110229504 | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2011-09-22 |
20110229505 | Methods for the diagnosis and treatment of cancer based on AVL9 - The present invention relates to methods for the diagnosis and treatment of cancer in mammals, in particular gastric cancer, based on the new target AVL9. The present invention thus relates to diagnostic methods and related components to be used in such methods. Furthermore, the present invention relates to the treatment of cancer in mammals, in particular gastric cancer, based on AVL9 as a target. Specifically, the present invention relates to the immunotherapy of cancer using AVL9 tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides, and respective pharmaceutical compositions, in particular vaccine compositions. | 2011-09-22 |
20110229506 | METHOD FOR CANCER IMMUNOTHERAPY - A novel compound of the formula (1): | 2011-09-22 |
20110229507 | STABLE ANTHRAX VACCINE FORMULATIONS - Formulations of anthrax protective antigen are provided that are stable in storage for prolonged periods. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against anthrax infection. | 2011-09-22 |
20110229508 | POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS - The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides and compositions thereof. SEQ ID NO: 1 is a full length | 2011-09-22 |
20110229509 | POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS - Disclosed are polypeptides comprising an amino acid sequence structurally related to SEQ ID NO 1 and uses of such polypeptides and compositions thereof. SEQ ID NO 1 is a full length | 2011-09-22 |
20110229510 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF - Glycopeptide conjugates, and methods of making and using such conjugates are disclosed. Certain glycopeptide conjugates comprise tumor associated carbohydrate antigens and peptide epitopes. Certain glycopeptide conjugates comprise cyclic peptide scaffolds that display carbohydrate antigens in a clustered fashion. The immunogenicity of select glycopeptide conjugates is demonstrated. | 2011-09-22 |
20110229511 | METHOD OF MODIFYING THE IMMUNE RESPONSE - Methods of neutralising circulating antibody and mitigating the risk of clinically significant adverse responses to incompatible transfusions and transplantations are described. The methods comprise the administration to the subject of dispersible antigen-lipid constructs. | 2011-09-22 |
20110229513 | LPS Based Vaccines - The removal of the glycosidic phosphate from the reducing end of the derived LPS molecule creates an aldehydo functionality which causes the formation of an immunologically dominant neo-epitope. Conjugation to the reducing end of a carbohydrate molecule following removal of the glycosidic phosphate traps the reducing glucosamine residue in an open-chain form which surprisingly was found to dominate the immune response. We therefore modified our conjugation strategy to avoid this open-chain form, by utilising the amino functionality created by the isolated amidase activity from | 2011-09-22 |
20110229514 | VACCINE AND IMMUNIZATION METHOD USING PLASMODIUM ANTIGEN 2 - A vaccine comprising an immunogenic preparation containing a | 2011-09-22 |
20110229515 | IDENTIFICATION OF GENES - A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of:
| 2011-09-22 |
20110229516 | ADJUVANT PHASE INVERSION CONCENTRATED NANOEMULSION COMPOSITIONS - Vaccine adjuvant food nanoemulsion compositions comprising a food safe nonionic surfactant, a hydrophobic food flavorant (e.g., an essential oil), a kosmotrope, and water. The nanoemulsion composition can be used as a vaccine adjuvant composition to enhance inactivated antigens, including protein antigens. Such compositions may be delivered as a nasal or oral spray. The compositions may inherently contain natural antimicrobials and antioxidants and are advantageous over other compositions which often require preservatives, flavorings and antimicrobials. | 2011-09-22 |
20110229517 | SYSTEM AND PROCESS FOR PRODUCING MULTI-COMPONENT BIOPHARMACEUTICALS - A sterile, closed, disposable system for formulating biopharmaceutical compositions containing multiple active agents is described herein. | 2011-09-22 |
20110229518 | OPTIMIZED INFLUENZA VACCINES - The invention concerns nucleotides vaccines encoding influenza proteins with few or no glycosylation sites. Since these first introductions of pandemic influenzas the viruses have drifted, accumulating mutations at antigenic sites, but also the N-glycosylation pattern has changed during the drifted years, accumulating N-linked glycosylation sequons that help mask the antigenic sites for recognition by the host immune system. These “naked” initial haemagglutinins induce a broad cross reactivity against widely drifted influenza subtypes. The origin of the DNA or RNA can be both pandemic influenza strains, which codes for proteins which have a naturally low content of glycosylation sites and/or DNA or RNA from non-pandemic influenza strains where the nucleotides have been mutated or changed so it encodes for proteins with less or no glycosylation sites. The invention also discloses DNA or RNA encoding the haemagglutinin (HA) from pandemic influenza A, e.g. the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, optionally with the Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from these pandemic influenza virus included, mixed together with DNA or RNA from non-pandemic influenza A as a vaccine against present day and future influenza A viruses. | 2011-09-22 |
20110229519 | VACCINE COMPOSITION FOR USE AGAINST INFLUENZA - The present invention relates to a vaccine composition comprising: —at least one prophylactically active agent against influenza, and —at least one adjuvant, said adjuvant being a derivative of a galactosylceramide, for use in the treatment of influenza. | 2011-09-22 |
20110229520 | MUTANT PESTIVIRUS WITH MUTATIONS IN CORE GENE AND NS3 REGION - The present invention relates to mutant Pestiviruses, and vaccines containing said viruses. | 2011-09-22 |
20110229521 | NUTRITIONAL SUPPORT OF THE IMMUNE SYSTEM DURING ANTI-CANCER TREATMENT - The present invention relates to methods and immunonutritional compositions for preventing the impairment of the immune function during anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently augment or enhance the immunocompetence of an immune cell and the immunogenecity of a tumor cell of a subject undergoing anti-cancer therapy-induced apoptosis and tumor-cell-enhanced immunogenicity such that the innate and adaptive immune functions and normal physiology of the immune cell are preserved, which, in turn, lead to (i) a better tolerance and increased efficacy to anti-cancer therapy; (ii) transient augmentation or enhancement of immunocompetence of the immune cell and immunogenecity of the tumor cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened by anti-cancer therapy. | 2011-09-22 |
20110229522 | METHODS, COMPOSITIONS AND VACCINES RELATING TO NEISSERIA MENINGITIDIS ANTIBODIES - The invention provides compositions and methods for screening subjects at risk for contracting meningococcal disease and/or at risk for failing to elicit an immunogenic response to a vaccine against | 2011-09-22 |
20110229523 | MODIFICATION OF ALLERGENS FOR IMMUNOTHERAPY - The present invention relates to pharmaceutical compositions for immunotherapy, for example for immunotherapy of peanut allergy. Further, the present invention relates to methods for the preparation of the present pharmaceutical compositions for immunotherapy, and their use in immunotherapy. | 2011-09-22 |
20110229524 | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of Gastric Cancer and other cancers - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gastric cancers (GC). | 2011-09-22 |
20110229525 | MODULATION OF CYTOKINE SIGNALING - Cell penetrating suppressor of cytokine signaling (CP-SOCS) molecules engineered to be resistant to intracellular degradation are discussed. Methods of treating diseases associated with cytokine signaling include one or more CP-SOCS degradation resistant molecules. | 2011-09-22 |
20110229527 | DIRECTLY COMPRESSIBLE HIGH FUNCTIONALITY GRANULAR DIBASIC CALCIUM PHOSPHATE BASED CO-PROCESSED EXCIPIENT - An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular dibasic calcium phosphate based excipient is provided. The improved excipient comprises dibasic calcium phosphate, a binder and a disintegrant, and is formed by spraying a homogeneous slurry of the components. The improved excipient provides enhanced flowability/good flow properties, an increased API loading and blendability and higher compactibility as compared to the individual components, and as compared to excipients formed from the same materials by conventional methods. | 2011-09-22 |
20110229528 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY - The present invention provides polymers, compositions thereof, and polyplexes comprising said polymers. In particular, cationic polymers, pegylated versions thereof, and polynucleotide containing polyplexes comprising such polymers are provided. The invention further provides methods of using said polymers and polyplexes. | 2011-09-22 |
20110229529 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE - The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents. | 2011-09-22 |
20110229530 | PHARMACEUTICAL DOSAGE FORMS FOR TIME-SPECIFIC DRUG DELIVERY - The present invention refers to an oral dosage form intended for the time-controlled release of drugs comprising a container for one or more active ingredients optionally in admixture with pharmaceutically acceptable excipients, said container consisting of at least two parts or elements that can be joined together so as to seal the contents, at least one of said elements being composed of one or more hydrophilic polymers that undergo a decrease in the glassy-rubbery transition temperature when in contact with aqueous fluids, except for polymers with pH dependent solubility soluble only at pH values above 5, optionally in admixture with pharmaceutically acceptable excipients, the wall of the elements of the container being of such thickness as to delay the release of the contained drug with respect to the time of administration. | 2011-09-22 |
20110229531 | ANTI-PROTOZOA COMPOUNDS - Use of a compound in the control of growth of at least one organism of the order of Amoebida, wherein said compound is capable of modulating the histidine biosynthesis pathway, and/or the methionine biosynthesis pathway and/or a pathway branching from the histidine biosynthesis pathway and/or methionine biosynthesis pathway in said organism. | 2011-09-22 |
20110229532 | PROCESS FOR NANOEMULSIFICATION OF CURCUMIN AND DERIVATIVES OF CURCUMIN - A process for nanomulsification of highly lipophillic polyphenols compounds using non-ionic surfactant and a non-ionic co-solvent with the help of sonar energy, to enhance the aqueous solubility is disclosed herein. | 2011-09-22 |
20110229533 | EXTENDED RELEASE DOSAGE FORM - A membrane system comprising an interior wall, a fluid-permeable exterior wall surrounding the interior wall and an internal compartment defined by the membrane system, wherein fluid permeability of the interior wall is responsive to osmolarity of an osmotic core within the internal compartment are disclosed. A controlled release dosage form comprising the membrane system and a process for delivering an osmotically active formulation from an osmotic pump over an extended period of time are also disclosed. | 2011-09-22 |
20110229534 | Non-Irritating Oral Care Formulations - The present invention provides a unique oral care formulation comprising an anti-irritant amount of a salicylate salt and an effective amount of a taste enhancing agent. Certain embodiments further comprise an anti-inflammatory amount of an irritating agent, for example ketorolac. The oral care formulations may be used on various devices to treat and/or prevent mucosal irritations such as ulcerations. | 2011-09-22 |
20110229535 | COMPOSITION HAVING A SIRTUIN ACTIVATOR - The present invention concerns a composition having at least one sirtuin activator and a carrier system for the at least one sirtuin activator, wherein the carrier system includes lipid vesicles with one or more lipid membranes. To provide an improved action of sirtuin activators in living skin cells, it is proposed in accordance with the invention that the at least one sirtuin activator is contained in the lipid vesicles and the lipid vesicles have a positive surface charge, wherein the positive surface charge is afforded by the lipid vesicles in the lipid membrane or membranes in addition to the lipids from which the vesicles are made up having positively charged molecules as charge generators, wherein said charge generators are selected from quaternary ammonium compound | 2011-09-22 |
20110229536 | COMPOSITIONS FOR TOPICAL APPLICATION COMPRISING MICROENCAPSULATED COLORANTS - Color-changing cosmetic or therapeutic compositions for topical application are provided, comprising one or more active substances and one or more microencapsulated colorants, which upon application on the skin provide a changing color effect that indicates the delivery of the active substances from said composition onto the skin and/or gives to the skin a visual esthetical effect. | 2011-09-22 |
20110229537 | ORAL SUPPLEMENT - An oral supplement containing bilberry extract, quercetin, beta-carotene, co-enzyme Q-10, lipoic acid, vitamins, and minerals, which supports skin health, as well as a method of administering the same, alone and in conjunction with a topical skin care composition, is disclosed. | 2011-09-22 |
20110229538 | TOPICAL SKIN CARE COMPOSITION - Topical skin care compositions containing a combination of ascorbic acid or a derivative thereof, brown algae extract, and a blend of botanical extracts comprising cucumber extract, watercress extract, birch leaf extract, red clover extract, and St. John's wort extract, and, optionally, ginseng extract, as well as methods of using the same, are disclosed. | 2011-09-22 |
20110229539 | CHEWING GUM POSSESSING TOOTH CLEANING EFFECT AND A TEETH CLEANING METHOD - The invention relates to a chewing gum possessing tooth cleaning effects, excluding the tooth brush abrasive effect, which chewing gum when chewed on a daily basis as a tooth cleaning agent is capable of replacing the daily tooth brushing, whereby abrasive cleaning damages on teeth side surfaces and gingiva are avoided. | 2011-09-22 |
20110229540 | COSMETIC FORMULATIONS COMPRISING POROUS SILICON - A cosmetic formulation comprising porous silicon is described. | 2011-09-22 |
20110229541 | SOLID TEETH BLEACHING DEVICE - A teeth bleaching device ( | 2011-09-22 |
20110229542 | METHODS FOR IMPARTING ANTI-MICROBIAL, MICROBICIDAL PROPERTIES TO FABRICS, YARNS AND FILAMENTS, AND FABRICS, YARNS AND FILAMENTS EMBODYING SUCH PROPERTIES - An antimicrobial fabric and method for treating fabric to impart antimicrobial properties thereto by preparing an aqueous solution of eugenol, polyvinyl alcohol, and glyoxal, padding the fabric with the aqueous solution to achieve a preselected desired part by weight wet pickup, drying the fabric; and curing the fabric. | 2011-09-22 |
20110229543 | Formulation and Delivery of Bacillus Thuringiensis Subspecies Israelensis and Bacillus Sphaericus in Combination for Broadspectrum Activity and Management of Resistance to Biological Mosquito Larvicides - A method for controlling Dipteran larvae or a method for inhibiting the development of larvicidal resistance, controlling resistant populations and reducing resistance levels in Diptera by introducing a larvicidally-effective amount of a combination of a strain of | 2011-09-22 |
20110229544 | Methods for Inhibiting Gram-Postive Bacteria Using Non-Phospholipid Lipid Vesicules - The present invention relates generally to the field of antibacterials and to the treatment, inhibition and prevention of disorders caused by bacteria. More particularly, this 5 invention concerns a method for inhibiting gram-positive bacteria with a composition comprising at least one non-phospholpid lipid vesicle. | 2011-09-22 |
20110229545 | MELT EMULSIFICATION - The present invention generally relates to colloidal systems, which may include colloidal particles and/or other types of particles. One aspect of the invention is generally directed to a system comprising fluidic droplets that can be at least partially solidified, e.g., to form colloidal particles. In some embodiments, particles comprising an at least partially solid outer phase encapsulating an inner phase are formed. The inner phase may be any phase, e.g., a solid, a liquid, or a gas. In some cases, solidifying at least a portion of the outer phase of the droplets to form particles may increase the stability of the particles and/or the colloidal system containing the particles. In one set of embodiments, melting or liquefying the outer phase of the particles (for example, by heating the particle to a temperature above a threshold temperature) can allow release of an agent contained within the inner phase, and/or allow the inner phase to coalesce with a phase external to the particles. The melting temperature of the outer phase can be controlled in some embodiments such that the outer phase will melt above a predetermined temperature. In some embodiments, the particles may be formed to be essentially free of an auxiliary stabilizing agent. In some embodiments, an agent may be encapsulated within a particle with relatively high efficiency. Other aspects of the invention are generally directed to methods of making and using such colloidal systems, e.g., containing such particles, kits involving such colloidal systems, or the like. | 2011-09-22 |
20110229546 | TREATMENT OF DISSECTION, ANEURYSM, AND ATHEROSCLEROSIS USING GRANZYME B INHIBITORS - A method of medical treatment or prevention of a vasculopathy, comprising administering a therapeutically effective amount of a granzyme B inhibitor to a subject in need thereof is provided. In other aspects uses of Granzyme B inhibitors for treatment or for preparation of medicaments for treatment of a vasculopathy are provided. | 2011-09-22 |
20110229547 | PROCESS FOR PRODUCING INORGANIC INTERCONNECTED 3D OPEN CELL BONE SUBSTITUTES - The present invention relates to a process of using a heat responsive mixture to produce inorganic interconnected 3D open-cell bone substitutes which can be applied in the orthopedic or dental field for treatment of bone damage. The invention provides a simple and easily-controlled process of preparing porous inorganic bone substitute materials. | 2011-09-22 |
20110229548 | Implantable Medical Device With Poly(Vinylidene Fluoride-Co-Hexafluoropropylene)/Zotarolimus Drug Layer - This invention relates to an implantable medical device for and method of treating a vascular disease where the device is preferably a stent comprising a drug reservoir layer comprising poly(vinylidene fluoride-co-hexafluoropropylene) and zotarolimus. | 2011-09-22 |
20110229549 | Methods and Compositions for Enhancing Vascular Access - Disclosed is an implantable material comprising a biocompatible matrix and cells which, when provided to a vascular access structure, can promote functionality generally. For example, implantable material of the present invention can enhance maturation of an arteriovenous native fistula as well as prolong the fistula in a mature, functional state suitable for dialysis. Additionally, the present invention can promote formation of a functional arteriovenous graft suitable for dialysis as well as promote formation of a functional peripheral bypass graft. Implantable material can be configured as a flexible planar form or a flowable composition with shape retaining properties suitable for implantation at, adjacent or in the vicinity of an anastomoses or arteriovenous graft. According to the methods disclosed herein, the implantable material is provided to an exterior surface of a blood vessel. Certain embodiments of the flexible planar form define a slot. The materials and methods of the present invention comprises cells, preferably endothelial cells or cells having an endothelial-like phenotype. | 2011-09-22 |
20110229550 | Acid-Degradable and Bioerodible Modified Polyhydroxylated Materials - Compositions and methods of making a modified polyhydroxylated polymer comprising a polyhydroxylated polymer having reversibly modified hydroxyl groups, whereby the hydroxyl groups are modified by an acid-catalyzed reaction between a polydroxylated polymer and a reagent such as acetals, aldehydes, vinyl ethers and ketones such that the modified polyhydroxylated polymers become insoluble in water but freely soluble in common organic solvents allowing for the facile preparation of acid-sensitive materials. Materials made from these polymers can be made to degrade in a pH-dependent manner. Both hydrophobic and hydrophilic cargoes were successfully loaded into particles made from the present polymers using single and double emulsion techniques, respectively. Due to its ease of preparation, processability, pH-sensitivity, and biocompatibility, of the present modified polyhydroxylated polymers should find use in numerous drug delivery applications. | 2011-09-22 |
20110229551 | DRUG DELIVERY COMPOSITIONS AND METHODS USING NANOFIBER WEBS - Polymeric nanofibers have been developed which are useful in a variety of medical and other applications, such as filtration devices, medical prostheses, scaffolds for tissue engineering, wound dressings, controlled drug delivery systems, cosmetic skin masks, and protective clothing. These can be formed of any of a variety of different polymers, both non-biodegradable or biodegradable, and derived from synthetic or natural sources. | 2011-09-22 |
20110229552 | NOVEL mRNA SPLICE VARIANT OF THE DOUBLECORTIN-LIKE KINASE GENE AND ITS USE IN DIAGNOSIS AND THERAPY OF CANCERS OF NEUROECTODERMAL ORIGIN - The present invention relates to novel nucleic acid and protein molecules and their use in cancer therapy and diagnosis. | 2011-09-22 |
20110229553 | Plant Extract with Pharmacological Profile for Treating or Preventing Diseases, Dysfunctions and Disorders of the Central Nervous System, Neurodegenerative Disorders and Sequel from Vascular Dementia - Plant extracts for pharmaceutical compositions as acetylcholinesterase inhibitors useful as neuroprotectors, to manage depressive states and cognitive deficits of diverse etiologies, and for the treatment of neurodegenerative conditions, such as Alzheimer's and Parkinson's diseases, and the sequel from ischemic events. | 2011-09-22 |
20110229554 | INTRAVENOUS FORMULATIONS OF COENZYME Q10 (CoQ10) AND METHODS OF USE THEREOF - Disclosed herein are formulations suitable for parenteral administration of certain hydrophobic active agents such as Coenzyme Q10. Methods of preparing the same and methods of treatment of oncological disorders using the same are also provided herein. The formulations comprise an aqueous solution; a hydrophobic active agent dispersed to form a colloidal nano-dispersion of particles; and at least one of a dispersion stabilizing agent and an opsonization reducer wherein the colloidal nano-dispersion of the active agent is dispersed into nano-dispersion particles having a mean size of less than 200-nm. Methods of preparing the parenteral formulations comprise dispersing the hydrophobic active agent by high pressure homogenization by (1) adding hydrophobic active agent to a 65° C. bath of water and mixing to form a hydrophobic active agent/water mixture; (2) adding a dispersion stabilizing agent to the hydrophobic active agent/water mixture and mix at 65° C. to form a hydrophobic active agent/water/stabilizer mixture; (3) adding an opsonization reducer to form a hydrophobic active agent/water/stabilizer/reducer mixture; (4) pre-heating a Microfluidizer to 65° C.; and (5) processing by mixing the hydrophobic active agent/water/stabilizer/reducer mixture in the Microfluidizer at 65° C. such that a hydrophobic active agent colloidal nano-dispersion having a mean particle size less than 200-nm is formed. Provided herein are also methods of treating oncological disorders by administering formulations described herein to a subject such that treatment or prevention of the oncological disorder occurs. | 2011-09-22 |
20110229555 | INTRAVENOUS CURCUMIN AND DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE AND STRESS DISORDERS - Liposomal formulations and polymer conjugates of curcumin, curcumin analogues and derivatives thereof for parenteral administration are disclosed herein. The formulations are effective in the treatment of progressive supranuclear palsy, Alzheimer's disease (AD), Parkinson's disease (PD), Tauopathies or stress disorders including Post Traumatic Stress Disorder (PTSD). Curcumin crosses the blood brain barrier, localizes in the hippocampus and striata, prevents stress-induced neuronal cell damage, and stimulates neurogenesis and remediation of damaged neural circuits. | 2011-09-22 |
20110229556 | LIPID-COATED POLYMER PARTICLES FOR IMMUNE STIMULATION - The invention provides delivery systems comprised of lipid coated polymer core particles, as well as compositions, methods of synthesis, and methods of use thereof. The particles can be used to carry antigen and adjuvant, resulting in enhanced immune responses. | 2011-09-22 |
20110229557 | METHODS FOR TREATING EYE DISORDERS - The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at 5 least one siRNA which down regulates expression of a target gene associated with loss of the retinal ganglion cell, thereby inhibiting loss of the retinal ganglion cell in the subject. The methods of the invention also relate to the use of chemically modified siRNA compounds possessing structural motifs which down-regulate the expression of human genes expressed in retinal tissue in the mammalian eye. | 2011-09-22 |
20110229558 | AGENT FOR TREATING MYELOFIBROSIS - Disclosed is a substance delivery carrier for an extracellular matrix-producing cell in the bone marrow, which comprises a retinoid. Also disclosed is an agent for treating myelofibrosis by utilizing a substance capable of regulating the activity or proliferation of an extracellular matrix-producing cell in the bone marrow. | 2011-09-22 |
20110229559 | Drug Release From Nanoparticle-Coated Capsules - Methods of producing a controlled release formulation for an active substance are disclosed, wherein the methods involve dispersing a discontinuous phase comprising an active substance into a continuous phase so as to form a two-phase liquid system comprising droplets of said discontinuous phase, and allowing nanoparticles provided to the two-phase liquid system to congregate at the phase interface to thereby coat the surface of the droplets in at least one layer of said nanoparticles. The methods utilise a concentration of a suitable electrolyte which enhances the nanoparticle congregation such that the coating of nanoparticles on the surface of the droplets presents a semi-permeable barrier to the active substance, or otherwise utilise a amount of the active substance that is greater than the solubility limit of that active substance in the discontinous phase. Formulations comprising vitamin A (retinol) as the active substance for dermal delivery are specifically exemplified. | 2011-09-22 |
20110229560 | NLRC5 AS A TARGET FOR IMMUNE THERAPY - The present invention concerns the enhancement of immune response to microbial infection and/or inflammation-associated disease through at least partial inhibition of NLRC5. The inhibition may be of any suitable means, although in particular cases it is via siRNA agents. In specific embodiments, a particular domain of NLRC5 is targeted by the siRNA. | 2011-09-22 |
20110229561 | Extended Release Pharmaceutical Composition Of Entacapone Or Salts Thereof - There is provided an extended release pharmaceutical composition comprising from about 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising triple combination of from about 30 mg to about 300 mg of levodopa, 10 mg to about 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions. | 2011-09-22 |
20110229563 | Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity - A material comprising from 30 to 80% by weight of ursolic acid, from 2 to 25% by weight of oleanolic acid and from 1 to 68% by weight of triterpenoic acids other than ursolic acid or oleanolic acid, or derivatives of any of these acids, said percentages being based on total weight of said acids or derivatives and the percentages of said acids or derivatives adding up to 100%, can be used in the prevention or treatment of hypersensitivity and/or hyper-reactivity. | 2011-09-22 |
20110229564 | Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof - The present invention relates provides pharmaceutical compositions comprising an amorphous carvedilol salt and one or more pharmaceutically acceptable excipients, wherein the amorphous carvedilol salt is formed in situ during the preparation of the pharmaceutical composition. The amorphous carvedilol salt is preferably an amorphous carvedilol phosphate salt. The pharmaceutical compositions can be prepared by providing one or more inert cores; contacting the core or cores with a solution or a dispersion comprising carvedilol, an acid component and optionally a binder, in a solvent; removing the solvent; and optionally coating the core or cores with an extended release composition. Preferred pharmaceutical compositions contain both immediate-release pellets and at least one population of extended-release pellet. | 2011-09-22 |
20110229565 | Drug Delivery Composition Comprising a Self-Assembled Gelator - This invention discloses drug-delivery compositions, methods of making prodrugs, and methods of drug delivery using a self-assembled gelator. The backbone of the gelator can contain a drug or prodrug, such as acetaminophen or salicin. Additional drugs or agents can be encapsulated in the gelator. Enzymatic or hydrolytic cleavage can be used to release the drugs. | 2011-09-22 |
20110229566 | Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof - There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions. | 2011-09-22 |
20110229567 | SOLID PHARMACEUTICAL COMPOSITION - The present invention provides a solid preparation containing compound (I) or a salt thereof, a pH control agent and a calcium antagonist, which is superior in the dissolution property, stability and the like. | 2011-09-22 |
20110229568 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS - Described herein are peptide derivatives and peptidomimetics as inhibitors for transglutaminases, methods for their preparation, pharmaceutical compositions containing said compounds as well as uses of said transglutaminase inhibitors in particular for the treatment of coeliac disease and transglutaminase dependent diseases. | 2011-09-22 |
20110229569 | COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT - The present invention provides a composition exhibiting delayed transit through the gastrointestinal tract comprising one or more active agents, fenugreek fiber and at least one pharmaceutically acceptable excipient. The present invention further relates to gastroretentive dosage forms comprising fenugreek fibers. | 2011-09-22 |
20110229570 | ORALLY RAPIDLY DISINTEGRATING TABLET AND PROCESS FOR PRODUCING SAME - Disclosed is an orally rapidly disintegrating tablet characterized in that the tablet can be produced in a conventional tablet manufacturing facility and has a satisfactory level of hardness for practical applications, and the change in properties of the tablet (i.e., decreased in hardness of the tablet, and delay of the disintegration time of the tablet in the oral cavity) are rarely caused by factors such as humidity. The orally rapidly disintegrating tablet has hardness of 40N or more, can be disintegrated in the oral cavity within 60 seconds, and is produced by compressing of a mixture of (a) an active ingredient, (b) an excipient having good water wettability, (c) a water-insoluble polymer that is well compactible and does not substantially cause a decrease in the water wettability of the excipient and (d) a disintegrating agent. | 2011-09-22 |
20110229571 | Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker - Pharmaceutical compositions containing selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions containing Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes. | 2011-09-22 |
20110229572 | DELIVERY OF DRUG COMBINATIONS - A composition comprising microspheres of a polymer matrix, having two different pharmaceutical actives having complementary, usually synergistic, activity in killing cells. The compositions have particular utility for treating tumours. Useful combinations are doxorubicin with rapamycin, irinotecan with ibuprofen, ibuprofen with doxorubicin and irinotecan with doxorubicin. The polymer matrix is preferably a crosslinked polyvinyl alcohol. The drugs may be included in the same microsphere, or microspheres each with an individual pharmaceutical agent may be mixed together. The microspheres are preferably used in chemoembolisation of tumours. | 2011-09-22 |
20110229573 | PROCESS OF MANUFACTURING A LYOPHILIZED FAST DISSOLVING, MULTI-PHASIC DOSAGE FORM - A multi-phasic, lyophilized, fast-dissolving dosage form (FDDF) for the delivery of a pharmaceutically active ingredient is prepared by sequential dosing of a formulation containing a non-gelling matrix forming agent and a formulation containing a gelling gelatin. | 2011-09-22 |
20110229574 | POLYSACCHARIDE AND PROTEIN-POLYSACCHARIDE CROSS-LINKED HYDROGELS FOR SOFT TISSUE AUGMENTATION - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 2011-09-22 |
20110229575 | DEEP IMMERSION FLOTATION THERAPY FOR BURN VICTIMS - This invention provides compositions for and methods of treating burn wounds in a subject. | 2011-09-22 |
20110229576 | HOLLOW SILICA NANOSPHERES AND METHODS OF MAKING SAME - The disclosure provide hollow nanospheres and methods of making and using the same. The methods and compositions of the disclosure are useful for drug delivery and gene transfer. | 2011-09-22 |
20110229577 | BIOLOGICALLY ACTIVE SILICIC ACID - The present invention relates to low-molar mass condensed derivatives of silicic acid of sub-nano particle size characterised by particular structure and specific biological activities. Preparation methods and applications are presented for the here disclosed sub-nano silicic acid (SNSA) which interact with bio-molecules and modify significantly their structure and biological function. Preferred field of application of the inventive silicic acid derivatives is to modulate the structure and biological function of proteins particularly of those involved in reversible phosphorylation within biological signal transduction or membrane transport processes. Structure of the substances, methods for the preparation and stabilization, as well as pharmaceutical compositions comprising the substances and methods of application in the prevention, diagnosis and therapy of diseases are disclosed. | 2011-09-22 |
20110229578 | MODAFINIL ORAL LYOPHILIZATE - The invention concerns an oral lyophilizate comprising modafinil particles having a median diameter of about 10 to about 1000 μm in association with an appropriate amount of at least one excipient selected from the group consisting of fatty acid esters of glycerol, cyclic oligosaccharides, sweeteners or mixtures thereof. | 2011-09-22 |
20110229579 | Support Having Nanostructured Titanium Dioxide Film And Uses Thereof - The present invention relates to supports for bioassays and the use thereof in cell culturing and in cell-based methods and assays. More precisely, the invention provides solid materials coated with films of nanostructured titanium dioxide suitable for the immobilisation of viruses and for cell-adhesion. The nanostructured TiO | 2011-09-22 |
20110229580 | COMPOSITIONS AND METHODS FOR NANO-IN-MICRO PARTICLES - Disclosed herein are compositions, methods and kits for a microsphere with one or more entrapped nanoparticles. The method of preparation comprises atomizing a suspension comprising a polysaccharide and one or more nanoparticles into a solution comprising a cross linking agent. | 2011-09-22 |
20110229581 | RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS - The present invention is directed to releasable cationic lipids and nanoparticle compositions for the delivery of nucleic acids and methods of modulating an expression of a target gene using the same. In particular, the invention relates to cationic lipids including an acid labile linker, and nanoparticle compositions containing the same. | 2011-09-22 |
20110229582 | Acaricidal and/or insecticidal active ingredient combinations - The present invention relates to active ingredient combinations which are composed of a known dihydrofuranone derivative on the one hand and of other known active pesticidal ingredients on the other hand, and are suitable for controlling animal pests from the families of the Aleyrodidae, Thripidae, Psyllidae and Agromyzidae, and also, more particularly, from the order of the Acari. The invention also relates to combinations which consist of the abovementioned active ingredient combinations on the one hand and of beneficial species on the other hand and which are suitable for controlling animal pests. | 2011-09-22 |
20110229583 | Human Medicinal Treatment Typically Using Salt of Peroxymonosulfuric Acid - A medicinal drug is administered to a person for treating a medical condition of the person or/and for preventing the person from contracting the medical condition. The medical condition can be a bacterial infection, a eukaryotic infection, a prion-caused infection, a non-pathogenic inflammation, and, insofar as not covered by any of these four types of the medical condition, a fungal infection, a spore-caused infection, and a parasitic infection. A medicinal drug is similarly administered non-topically to a person for treating a virus-caused medical condition of the person or/and for preventing the person from contracting the virus-caused medical condition. The medicinal drug is typically formed at least partially with salt of peroxymonosulfuric acid, preferably potassium hydrogen peroxymonosulfate. | 2011-09-22 |
20110229584 | Compound for the control of herpes simplex virus using glycyrrhizic acid, lipoic acid, allantoin, and slippery elm - A Theraputic composition of glycyrrhizic acid, slippery elm, zinc oxide, allantoin, lysine monohydrochloride, L-Carnitine, Lipoic acid, Salicylic Acid, Citric Acid, vitamin E Acetate, wheat germ oil, and Shea butter for the treatment of HSV-1, HSV-2, canker sores, shingles, and other epidermal and oral ailments. | 2011-09-22 |
20110229585 | NUTRIENT COMPOSITIONS AND METHODS FOR ENHANCED EFFECTIVENESS OF THE IMMUNE SYSTEM - The invention provides a nutrient composition for augmenting immune strength or physiological detoxification. The nutrient composition consists of an optimal combination of an effective amount of at least one vitamin antioxidant, at least one mineral antioxidant and a highly saturable amount of at least three high potency antioxidants. The at least one vitamin antioxidant can be vitamin C, bioflavonoid complex, vitamin E, vitamin B6 or beta-carotene and the at least one mineral antioxidant can be zinc or selenium. The at least three high potency antioxidants can be alpha lipoic acid, acetyl L-carnitine, N-acetyl-cysteine, co-enzyme Q10 or glutathione. Also provided is a nutrient composition for augmenting immune strength or physiological detoxification that consists of an optimal combination of an effective amount of at least three vitamin antioxidants, at least two mineral antioxidants and a highly saturable amount of at least three high potency antioxidants. Further provided is a method of stimulating immune system function or a method of augmenting a therapeutic treatment of a disease. The method consists of administering to an individual a nutrient composition of the invention one or more times a day over a period of about 5-7 weeks, the immune system function being stimulated to result in an increase of CD4+ cells of at least about 15% compared to pre-administration levels. A method of stimulating a physiological detoxification function of an individual or a method of augmenting a therapeutic treatment of a disease is also provided. The method consists of administering to an individual a nutrient composition of the invention one or more times a day over a period of about 5-7 weeks, the physiological detoxification function being stimulated to result in a decrease of one or more free radical markers by about 20% compared to pre-administration levels. | 2011-09-22 |
20110229586 | CONTROL OF DEVELOPMENT OF BIOFILMS IN INDUSTRIAL PROCESS WATER - There is provided a method of inhibiting the development of a biofilm adjacent a surface, the method comprising intermittently applying a biofilm inhibiting substance to a collection of microorganisms having biofilm developing potential. Other embodiments are also described. | 2011-09-22 |
20110229587 | Calcium Supplements for the Treatment of Diabetes - Provided herein is a method for treating diabetes, said method comprising administering to a subject with diabetes a composition comprising calcium. | 2011-09-22 |
20110229588 | METHOD FOR THE REDUCTION OF THE CONCENTRATION OF AMINES AND SALTS THEREOF - The invention relates to a method for reducing the concentration of amines and salts thereof, wherein the amines have the general chemical formula I R1R2R3N and the salts have the formula II R1R2R3N—H, wherein the amines and salts thereof exist in aqueous solution or aqueous suspension and are brought into contact with clinoptilolitic or clinoptilolite-containing mixtures. The method itself is suitable for use in food preparation and in the manufacture of foods. The inventive idea of reducing the concentration of amines and salts thereof is also useful in the manufacture of medical products for absorbing and for removing amines from the intestinal tract or the skin area of humans and animals. | 2011-09-22 |
20110229589 | INSECT AND PLANT DISEASE CONTROL COMPOSITIONS AND METHODS OF USE THEREOF - A combination of plant essential oils in an aqueous solution containing vinegar provided a pesticidal effect against a range of pests, including fungi, bacteria, oomycetes, insects such as mosquitoes and bedbugs, and nematodes, and uses thereof. | 2011-09-22 |
20110229590 | PHARMACEUTICAL COMPOSITION COMPRISING GINGER EXTRACT OR SHOGAOL - The present invention provides a pharmaceutical composition for preventing or treating learning disorders, memory disorders, Parkinson's disease, or ischemic cerebrovascular disease, which comprises a ginger extract or shogaol; and a pharmaceutically acceptable carrier. And also, the present invention provides a food composition for improving learning disorders or memory disorders or alleviating the symptoms of learning disorders or memory disorders which comprises a ginger extract or shogaol as an active ingredient, or a food composition for improving learning or memory which comprises a ginger extract or shogaol as an active ingredient. | 2011-09-22 |
20110229591 | WITHANIA SOMNIFERA PLANT EXTRACT AND METHOD OF PREPARATION THEREOF - The present invention provides | 2011-09-22 |
20110229592 | Forming Machine That Quickly Compacts Hollow Materials and Automatically Recycles the Materials - A forming machine that quickly compacts hollow materials and automatically recycles the materials includes molds, each of which is provided with a feeder having a hollow hole. An opening of the feeder is exactly located at a hollow position of a food product to be formed, and an upper end of the hollow feeder is connected with recycling tubes coming from a feed tank. When a cope and a nowel compact and form the materials into the hollow food products, the feeders will automatically push upward remainders at hollow places of the food products that are stacked constantly, enabling the remainders to enter into the feed tank along the recycling tubes, so as to achieve effects of quickly compacting and processing the materials and automatically recycling the remainders. | 2011-09-22 |
20110229593 | PNEUMATIC VALVE DEVICE FOR EJECTING MOULDED ARTICLES OF PLASTIC MATERIAL FROM A MOULD - A pneumatic valve device ( | 2011-09-22 |
20110229594 | APPARATUS FOR PRODUCING A POLYMER PELLET - An apparatus for producing a polymer pellet is provided. The apparatus includes a conveying mechanism configured to convey a coated polymer, a supporting mechanism configured to support the coated polymer, a supporting plate having a deforming and cutting mechanism configured to deform and cut the coated polymer, a reciprocating mechanism configured to reciprocate the supporting plate upwardly and downwardly, and a collector configured to collect cut pellets. The reciprocating mechanism holds the supporting plate so that the deforming and cutting mechanism faces the coated polymer. | 2011-09-22 |
20110229595 | CASTING, MOLDING OR PRESSING TOOL WITH TEMPERATURE CONTROL MEDIUM CHANNELS - In a method of producing a casting, molding or pressing tool ( | 2011-09-22 |
20110229596 | Ejector Device for an Injection Molding Machine - An ejector device is mounted in an injection molding machine and has a base, a driving assembly mounted through the base and a hydraulic cylinder and a transmission assembly driving the driving assembly. The driving assembly is further connected to a rotating die of a die assembly and moves recipricatorily and rotates the rotating die to displace a semi-manufactured plastic article from one set of die faces to another set of die faces to form another plastic layer. Thus, a plastic article with multiple layers or multiple colors is formed in one injection molding machine. | 2011-09-22 |
20110229597 | IMPROVED CHECK VALVE - A check valve ( | 2011-09-22 |
20110229598 | Enhanced lactoperoxidase system for treatment of milk products - The present invention relates to treatment of milk and milk products such as waste-milk with an enhanced lactoperoxidase system. The enhanced lactoperoxidase system is activated by the addition of a hydrogen peroxide source and an oxidizable agent, such as a halide to the milk to inactivate the bacterial pathogens. The enhanced lactoperoxidase system may be used alone or in conjunction with pasteurization to reduce or eliminate the bacterial load in milk products. | 2011-09-22 |
20110229599 | Modification of feed consumption patterns in beef cattle rations - The present invention relates to feed compositions that can modify the feeding behavior of animals. Supplements can be added to no or low roughage rations that improve the performance of animals. In particular, the addition of calcium chloride to a low or no roughage ration can increase the number of feedings but decrease the amount of feeding per meal. This can result in promoting enhances feed conversion and better cost of feed to weight gain. | 2011-09-22 |
20110229600 | SN-2 MYRISTATE-CONTAINING EDIBLE OIL - A nutritional fat or oil-based composition for increasing HDL cholesterol, decreasing LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma is described. The composition can advantageously include at least 1% by weight myristic acid esterified at the sn-2 position in triglyceride molecules, includes between 10% and 40% by weight linoleic acid, and further includes between 30% and 65% by weight oleic acid and between 15% and 40% by weight total saturated fatty acids. The ratio of sn-2 myristic acid to sn-2 palmitic acid is typically greater than 1:1 and the sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. | 2011-09-22 |
20110229601 | CHEWING GUM CONTAINING LOW DOSE AMOUNTS OF WATER SOLUBLE VITAMINS - Chewable compositions containing at least 20% of recommended daily allowance of water-soluble vitamins are used to maintain a beneficial amount of such vitamins in a consumer's bloodstream throughout a day. Use of such chewable compositions may be supplemented by additional single dose intake of such water-soluble vitamins. | 2011-09-22 |